The Zacks Analyst Blog Highlights: Actelion, Bayer, Pfizer, Gilead Sciences and Honeywell International PR Newswire CHICAGO, Nov. 6, 2013 CHICAGO, Nov. 6, 2013 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Actelion Ltd. (OTC:ALIOF-Free Report), Bayer (OTC:BAYRY-Free Report) Pfizer Inc. (NYSE:PFE-Free Report), Gilead Sciences Inc. (Nasdaq:GILD-Free Report) and Honeywell International Inc (NYSE:HON-Free Report). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free. Here are highlights from Tuesday's Analyst Blog: U.S. Launch of Actelion Hypertension Med Actelion Ltd. (OTC:ALIOF-Free Report) announced the launch of Opsumit 10 mg in the U.S. for the treatment of patients suffering from pulmonary arterial hypertension (PAH WHO Group I) to delay disease progression. Disease progression includes events like death, commencement of intravenous or subcutaneous prostanoids or clinical worsening of PAH. The SERAPHIN study established the effectiveness of Opsumit in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years. Opsumit was approved by the U.S. Food and Drug Administration on Oct 18, 2013 The approval of the drug in the EU for the PAH indication is also on track. Last month, Actelion received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Opsumit. Actelion is looking to get Opsumit approved in the EU as monotherapy or in combination, for the long-term treatment of PAH in adults of WHO functional class II to III. A final decision on Opsumit should be out by year end. It has also filed for approval in other regions. Opsumit is also being evaluated in a pivotal phase III program in patients suffering from digital ulcers associated with systemic sclerosis. Results from this study are expected in the first half of 2014. In addition, Opsumit is being evaluated for the treatment of glioblastoma (phase I). We believe the launch of Opsumit in the U.S. will strengthen Actelion's cardiovascular portfolio. Opsumit is the first drug to have proved its efficacy in delaying disease progression over the long term in PAH patients. However, the PAH market looks extremely competitive with the presence of Bayer's (OTC:BAYRY-Free Report) Adempas, Pfizer Inc.'s (NYSE:PFE-Free Report) Revatio and Gilead Sciences Inc.'s (Nasdaq:GILD-Free Report) Letairis. Actelion carries a Zacks Rank #1 (Strong Buy) while Bayer is a Zacks #2 (Buy) Ranked stock. Refinery Modernization by Honeywell Honeywell International Inc (NYSE:HON-Free Report) was recently selected by Swedish oil producer Preem AB to modernize one of Europe's largest refineries. Honeywell's Enhanced High Performance Process Manager (EHPM) industrial process controllers will help Preem to upgrade the refinery and increase through-put while maximizing legacy investments and intellectual property. The upgrade is expected to be complete before the end of this year. Additionally, the adoption of other technologies by Honeywell can also be used by Preem to enhance its overall refinery operations. These include continuous and batch processing controls such as Experion C300, and Honeywell's fault tolerant ethernet FTE technology that offer faster network diagnostics and improved security. The technological up-gradation is cost effective for the company as it saves on time and cost of entire control system replacement. The project should considerably extend the life of the existing control system at the refinery. At the same time, the enhanced high-performance process manager will triple the capacity of the refinery's existing controllers. Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free. About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today. About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros. Get the full Report on ALIOF - FREE Get the full Report on BAYRY - FREE Get the full Report on PFE - FREE Get the full Report on GILD - FREE Get the full Report on HON - FRE Follow us on Twitter: http://twitter.com/zacksresearch Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 firstname.lastname@example.org http://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumedthat any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein andis subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release. SOURCE Zacks Investment Research, Inc. Website: http://www.zacks.com
The Zacks Analyst Blog Highlights: Actelion, Bayer, Pfizer, Gilead Sciences and Honeywell International
Press spacebar to pause and continue. Press esc to stop.